Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 2Recurrence 1Pheochromocytoma 1Insulinoma 1Hypoglycemia 1Hyperinsulinism 1Glioblastoma 1Endocrine System Diseases 1Congenital Hyperinsulinism 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 24Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × fluorodopa F 18 × Clear all
NCT02176720 2018-08-17

Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma

The Methodist Hospital Research Institute

Phase 1 Terminated
31 enrolled
CNS

Glioblastoma, Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡